When was Biotia founded?

Biotia was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is Biotia located?

Biotia is headquartered in Brooklyn, United States. It is registered at 1867 STOCKHOLM ST.,APT. 1,RIDGEWOOD,NY,11385.

Who is the current CEO of Biotia?

Niamh O'Hara of Biotia. They have also founded 1 company.

How many employees does Biotia have?

As of May 31, 2026, the latest employee count at Biotia is 26.

Is Biotia a funded company?

Biotia is a funded company, having raised a total of $10.4M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 10, 2019.

When was the latest funding round of Biotia?

Biotia's latest funding was a $***** Series A round on Aug 23, 2022, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.3B in funding in 2026 to date.

Where does Biotia rank among its competitors?

Biotia ranks 1st amongst 40 active competitors, of which 19 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was mbiomics, which secured $14.1M in Apr, 2026.

Who are the top competitors of Biotia?

Biotia's top competitors include Kallyope, mbiomics and BioCorteX. Among them, mbiomics secured the most recent funding round in April, 2026.

Biotia - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of sequencing-based solutions for hospitals. The company uses its proprietary bioinformatics technology to fight nosocomial infections and other diseases. The company offers active surveillance of the highest risk units, and incoming patients, and facilitates intervention before patients get sick.

Website: www.biotia.io/
Social
Email ID: *****@biotia.io
Registered Address: 1867 STOCKHOLM ST.,APT. 1,RIDGEWOOD,NY,11385

Key Metrics

Founded Year

2016

Location

Brooklyn, United States

Stage

Series A

Total Funding

$10.4M in 2 rounds

Latest Funding Round

Series A, Aug 23, 2022, $*****

Investors

OCA Ventures & 17 more

Ranked

1^st among 40 active competitors

Employee Count

26 as on May 31, 2026

Similar Companies

Kallyope & 51 more

View Biotia's full profile

Biotia is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIOTIA, INC. CIN: 5347761 , United States, Active	May 24, 2018	-	-	-

Biotia has raised a total funding of $10.4M over 2 rounds. Its first funding round was on Dec 10, 2019. Its latest funding round was a Series A round on Aug 23, 2022 for $*****. 6 investors participated in its latest round. Biotia has 18 institutional investors.

Here is the list of recent funding rounds of Biotia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 23, 2022	7348411	Series A	1797930	6369190	5039522	4616069
Dec 10, 2019	8417153	Seed	5779104	8496667	Hyperplane & 3 more	7256884

Access funding benchmarks and valuations. Sign up today!

View details of Biotia's funding rounds and investors

The founders of Biotia is Niamh O'Hara. Niamh O'Hara is the CEO of Biotia.

Here are the details of Biotia's key team members:

Niamh O'Hara: Co-Founder & CEO of Biotia.
Contact Info: 1 email address

View details of Biotia's Founder profiles and Board Members

Biotia's employee count trend

Biotia has 26 employees as of May 26. Here is Biotia's employee count trend over the years:

Uncover Biotia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biotia include Kallyope, mbiomics and BioCorteX. Here is the list of Top 10 competitors of Biotia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biotia 2016, Brooklyn (United States), Series A	Provider of sequencing-based solutions for hospitals	$10.4M	OCA Ventures, Leawood Venture Capital & 16 others	59/100
2nd	Kallyope 2014, New York City (United States), Series D	Discovering novel therapeutics for neurological and metabolic diseases	$479M	The Column Group, Lux Capital & 21 others	59/100
3rd	mbiomics 2020, Munich (Germany), Series A	Provider of a genomic-based platform for microbiome-based therapeutics development	$35.2M	MIG Fonds, Bayern Kapital & 1 others	55/100
4th	BioCorteX 2021, London (United Kingdom), Seed	Developer of human-microbiome platform for drug development	$5M	Sofinnova Partners, Hoxton Ventures & 1 others	53/100
5th	Manus Bio 2011, Cambridge (United States), Series B	Developer of phytochemicals using microbial fermentation	$125M	Nelstone Ventures, BBGI & 17 others	52/100
6th	Kaleido Biosciences 2015, Cambridge (United States), Deadpooled	Developer of microbiome metabolic therapies for inflammatory conditions	$165M	Fidelity Investments, Invus & 7 others	44/100
7th	MicroByre 2017, San Francisco (United States), Seed	Developer of genetically engineered strains of microorganisms	$7.67M	Planetary Technologies, Climate Capital & 6 others	44/100
8th	MicroGen Diagnostics 2011, Orlando (United States), Seed	Provider of sequencing and molecular diagnostic services	$1.65M	-	43/100
9th	Neoprospecta 2010, Florianopolis (Brazil), Seed	Provider of NGS for microbiome analysis and monitoring for various applications	$1.78M	CVentures, Catarina Capital & 4 others	40/100
10th	Photanol 2008, Amsterdam (Netherlands), Series A	Provider of technology for light-powered bio-production of chemicals	$9.3M	UvA Ventures Holding, EIC Fund & 3 others	40/100